A5042297385- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Ferroptosis and cancer prognosis
- Cancer-related molecular mechanisms research
- Lung Cancer Diagnosis and Treatment
- Cancer Research and Treatments
- MicroRNA in disease regulation
- Immune cells in cancer
- Colorectal Cancer Screening and Detection
- Genetic factors in colorectal cancer
- COVID-19 diagnosis using AI
- Cancer Mechanisms and Therapy
- Atomic and Subatomic Physics Research
Chinese PLA General Hospital
2022-2025
PLA Academy of Military Science
2024
Chinese People's Liberation Army
2020-2023
Chinese General Hospital College of Nursing and Liberal Arts
2023
People's Liberation Army No. 150 Hospital
2020-2022
Abstract Objectives The use of immune checkpoint inhibitors, particularly PD‐1 has revolutionized the treatment advanced tumors and shown significant improvements in patient survival rates. However, which inhibitor is more effective safer for a specific indication remains unclear. To address this problem, our study aimed to evaluate effectiveness safety different inhibitors combination with chemotherapy as first‐line therapy individuals non‐small‐cell lung cancer (NSCLC) without driver genes...
8090 Background: Extensive-stage small cell lung cancer (ES-SCLC) is related to high malignancy and the poor prognosis. At present, immunotherapy combined with chemotherapy resulted in favorable therapeutic efficacy, had been established as standard treatment regimen for first-line of ES-SCLC. However, some patients may still experience intolerable AEs over course treatment, such immune-related pneumonitis enteritis. Additionally, currently marketed ICIs were administered by continuous...
Anti-programmed death-1 (PD-1) therapy has been extensively used to treat cancer. Recently, the combination of immunotherapy and anti-angiogenic emerged as a novel treatment approach. Therefore, we designed study evaluate real-world benefit anti-PD-1 anti-angiogenesis in patients with non-small cell lung cancer (NSCLC).We obtained medical records at Chinese People's Liberation Army General Hospital who received either nivolumab or pembrolizumab combined from January 2015 December 2018. The...
Immunotherapy has transformed cancer treatment patterns for advanced hepatocellular carcinoma (aHCC) in recent years. Therefore, the identification of predictive biomarkers important clinical implications.We collected medical records from 117 aHCC patients treated with anti-PD-1 antibody. Kaplan-Meier analysis and Cox proportional hazard regression were used to evaluate association between peripheral blood overall survival (OS) progression-free (PFS). Finally, prognostic nomogram was...
Colorectal cancer (CRC) is a major public health concern and the second leading cause of cancer-related deaths worldwide. However, challenges remain in deploying effective screening strategies for early-stage CRC. This study aimed to evaluate effectiveness fecal-based syndecan-2 (SDC2) methylation test detection colorectal lesions We retrospectively collected data on participants who underwent fecal SDC2 testing from January 1, 2019, May 30, 2023. Patients with positive results were...
Tumor-infiltrating immune cells (TICs) play a central role in the tumor microenvironment, which can reflect host anti-tumor response. However, few studies have explored TICs predicting prognosis of lung adenocarcinoma (LUAD). In our study, we enrolled 2470 LUAD patients from TCGA and GEO databases, normalized enrichment scores for 65 cell types were quantified each patient. An immune-related risk score (IRRS) was built on basis 17 selected using LASSO regression analysis, results showed that...
Purpose: This study aims to investigate the process of small cell lung cancer (SCLC) patients from achieving optimal efficacy experiencing disease progression until death. It examines predictive value treatment response on free survival (PFS) and overall (OS) SCLC patients. Patients Methods: We conducted a retrospective analysis 136 diagnosed 1992 2018. Important prognostic factors were identified construct nomogram models. The performance models was evaluated using receiver operating...
Immune checkpoint inhibitors (ICIs) have changed the treatment landscape of several cancer types. However, data are lacking with regard to clinical responsiveness ICIs in patients advanced non-small cell lung (NSCLC) after standard first-line chemotherapy. Therefore, we aimed evaluate efficacy ICI alone or combination chemotherapy for NSCLC platinum-based chemotherapy.We retrospectively collected confirmed who underwent monotherapy plus between January 2018 and December 2020. A propensity...
Abstract Background: Immunotherapy has transformed cancer treatment patterns for advanced hepatocellular carcinoma (aHCC) in recent years. Therefore, the identification of predictive biomarkers important clinical implications. Methods: We collected medical records from 117 aHCC patients treated with anti-PD-1 antibody. Kaplan-Meier analysis and Cox proportional hazard regression were used to evaluate association between peripheral blood overall survival (OS) progression-free (PFS). Finally,...
e20564 Background: In recent years, treatment for advanced or metastatic NSCLC has been significantly improved with the emergence of a combination strategy immunotherapy antiangiogenic drugs plus chemotherapy. Although endostatin (an agent) combined chemotherapy approved by China Food and Drug Administration in treatment-naïve re-treatment patients, clinical evidence supporting its programmed cell death-1 (PD-1) antibody is still insufficient. Therefore, we aimed to evaluate effectiveness...